Vivacitas Oncology and IAG Partner to Integrate Novel Imagin

Vivacitas Oncology and IAG Partner to Integrate Novel Imaging Markers in the Development of AR-67 in Recurrent Glioblastoma Patients


Vivacitas Oncology and IAG Partner to Integrate Novel Imaging Markers in the Development of AR-67 in Recurrent Glioblastoma Patients
ACCESSWIRE
WALNUT CREEK, CA and LONDON, UK / ACCESSWIRE / May 3, 2021 / Vivacitas Oncology, Inc. ('
Vivacitas' or the '
Company'), a clinical stage biopharmaceutical company focused on tough to treat cancers, and Image Analysis Group ('IAG'), a leading global medical imaging company, are collaborating to apply Artificial Intelligence (AI) technology and advanced imaging strategies to further the development of AR-67, a third generation Camptothecin, in patients with recurrent glioblastoma multiforme (reGBM).
Advanced imaging techniques could play a critical role in response assessment in developing new and innovative cancer therapies. Multiparametric magnetic resonance imaging (mpMRI) provides quantitative non-invasive imaging markers of early therapy-related changes. IAG is deploying its proprietary, cloud-based imaging approach to provide scientific evidence of early therapy response.

Related Keywords

London , City Of , United Kingdom , Tina Runk , Diana Dupont Roettger , Joseph Rubinfeld , Amgen , Scientific Alliance , Image Analysis Group , Vivacitas Oncology Inc , Vivacitas Oncology , Artificial Intelligence , Executive Vice President , Clinical Operations , Chief Scientific Alliance Officer , Analysis Group , Machine Learning , லண்டன் , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , மகேன் , அறிவியல் கூட்டணி , படம் பகுப்பாய்வு குழு , செயற்கை உளவுத்துறை , நிர்வாகி துணை ப்ரெஸிடெஂட் , மருத்துவ செயல்பாடுகள் , பகுப்பாய்வு குழு , இயந்திரம் கற்றல் ,

© 2025 Vimarsana